OR WAIT null SECS
Becton, Dickinson, and Company and partner Aptar’s new plunger stopper will support the injection of biologics into subcutaneous tissue.
Becton, Dickinson, and Company (BD)’s BD SCF PremiumCoat Plunger Stopperade in partnership with Aptar Pharma, has been designed to support the injection of biologics into subcutaneous tissue with a -mL pre-filled syringe. BD and Aptar Pharma introduced the new stopper in October 2021.
The plunger stopper uses Aptar Pharma’s rubber formulation and film technology that is designed to limit drug component interactions and ensure drug integrity. According to an Oct. 13, 2021 BD press release, the product is designed to deliver improved functional performance, such as reduced glide force and glide force variability, in combination products. Quality of the stopper is verified in part through BD Viosioguard 100% camera inspection, which aims to ensure the product meets customer specifications and reduce the risk of foreign matter contamination.
“Biologics represent a critical and fast-growing segment of the drug market in the fight against serious diseases,” said Eric Borin, worldwide president of BD Medical-Pharmaceutical Systems, in the press release. “Enhanced biologic combination products are needed to ensure that patients and their caregivers can administer these drugs from the comfort of their homes. This partnership with Aptar Pharma will help deliver on that need.”
“The launch of BD SC PremiumCoat Plunger Stopper, merging BD and Aptar Pharma’s expertise, brings a new generation of coated plunger stopper solutions to the market to support the protection of sensitive drugs by reducing the quantity and species of probable leachables,” said Gabriel Zenker, president, Aptar Pharma Injectables, in the press release. “In partnering with BD, we look forward to furthering our support of biotech companies in their efforts to provide safe and easy-to-use drug delivery systems, while we continue to invest in new technologies to address the evolving needs of [the] market.”